FDA approves Eisai’s Aciphex for ages 12 and up

WOODCLIFF LAKE, N.J. The Food and Drug Administration has approved Aciphex for treatment of gastroesophageal reflux disease in adolescents age 12 and older, Tokyo-based Eisai’s North America subsidiary announced Monday.

Aciphex, known generically as rabeprazole sodium, is available in 20 mg tablets for treating GERD for up to eight weeks.

Eisai discovered and developed the drug and promotes it in the United States with PriCara, a division of Ortho-McNeil-Janssen Pharmaceuticals.